Ligand Pharmaceuticals Incorporated
US ˙ NasdaqGM ˙ US53220K5048

SecurityLGND / Ligand Pharmaceuticals Incorporated
InstitutionWoodstock Corp
Latest Disclosed Ownership19,120 shares
Latest Disclosed Value $ 3,817,308
Woodstock Corp reports 4.42% decrease in ownership of LGND / Ligand Pharmaceuticals Incorporated

On April 8, 2026 - Woodstock Corp filed a 13F-HR form disclosing ownership of 19,120 shares of Ligand Pharmaceuticals Incorporated (US:LGND) valued at $3,817,308 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 14, 2026 disclosing 20,005 shares of Ligand Pharmaceuticals Incorporated. This represents a change in shares of -4.42% during the quarter. The current value of the position is $4,531,440 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-08 2026-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 19,120 -885 -4.42 3,817 0.93 0.3398
2026-01-14 2025-12-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 20,005 -20 -0.10 3,782 6.63 0.3246
2025-10-07 2025-09-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 20,025 -9,472 -32.11 3,547 5.79 0.3074
2025-07-09 2025-06-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 29,497 100 0.34 3,353 8.51 0.3082
2025-04-09 2025-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 29,397 -14 -0.05 3,091 -1.94 0.3053
2025-01-15 2024-12-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 29,411 200 0.68 3,151 7.80 0.3036
2024-10-11 2024-09-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 29,211 100 0.34 2,924 19.21 0.2813
2024-07-08 2024-06-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 29,111 -1,000 -3.32 2,453 11.40 0.2494
2024-04-09 2024-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 30,111 0 0.00 2,201 2.37 0.2279
2024-01-08 2023-12-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 30,111 -4,049 -11.85 2,151 5.08 0.2490
2023-10-10 2023-09-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 34,160 -12,635 -27.00 2,047 -39.34 0.2567
2023-07-07 2023-06-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 46,795 -5,809 -11.04 3,374 -12.82 0.3981
2023-04-06 2023-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 52,604 -2,410 -4.38 3,870 5.31 0.4935
2023-01-10 2022-12-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 55,014 -6,680 -10.83 3,675 -30.84 0.4884
2022-10-11 2022-09-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 61,694 -2,206 -3.45 5,312 -6.82 0.7903
2022-07-11 2022-06-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 63,900 -150 -0.23 5,701 -20.87 0.7913
2022-04-07 2022-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 64,050 -4,616 -6.72 7,205 -32.07 0.8437
2022-01-07 2021-12-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 68,666 0 0.00 10,606 10.86 1.1105
2021-10-05 2021-09-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 68,666 -110 -0.16 9,567 6.03 1.1157
2021-07-06 2021-06-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 68,776 0 0.00 9,023 -13.94 1.0617
2021-04-05 2021-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 68,776 -707 -1.02 10,485 51.74 1.3330
2021-01-06 2020-12-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 69,483 20 0.03 6,910 4.36 0.9249
2020-10-02 2020-09-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 69,463 -1,460 -2.06 6,621 -16.54 1.0692
2020-07-07 2020-06-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 70,923 106 0.15 7,933 54.04 1.3523
2020-04-03 2020-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 70,817 -672 -0.94 5,150 -30.93 1.0494
2020-01-13 2019-12-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 71,489 241 0.34 7,456 5.13 1.2144
2019-10-02 2019-09-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 71,248 65 0.09 7,092 -12.72 1.2356
2019-07-03 2019-06-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 71,183 430 0.61 8,126 -8.64 1.4187
2019-04-05 2019-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 70,753 994 1.42 8,894 -6.04 1.5934
2019-01-08 2018-12-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 69,759 3,051 4.57 9,466 -48.30 1.8995
2018-10-03 2018-09-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 66,708 -1,188 -1.75 18,311 30.18 3.0948
2018-07-23 2018-06-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 67,896 -1,075 -1.56 14,066 23.48 2.5894
2018-04-19 2018-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 68,971 -177 -0.26 11,391 20.31 2.1539
2018-01-24 2017-12-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 69,148 213 0.31 9,468 0.87 1.7462
2017-10-06 2017-09-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 68,935 730 1.07 9,386 13.36 1.7892
2017-07-13 2017-06-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 68,205 1,290 1.93 8,280 16.92 1.6229
2017-04-05 2017-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 66,915 626 0.94 7,082 5.14 1.4274
2017-01-05 2016-12-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 66,289 -856 -1.27 6,736 -1.71 1.3655
2016-10-06 2016-09-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 67,145 -1,893 -2.74 6,853 -16.77 1.4023
2016-08-03 2016-06-30 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 69,038 -360 -0.52 8,234 10.79 1.6995
2016-05-10 2016-03-31 13F Ligand Pharmaceuticals COMMON STOCK 53220K504 69,398 0 0.00 7,432 -1.22 1.5635
2016-01-11 2015-12-31 13F LIGAND PHARMACEUTICALS INC B COMMON STOCK 53220K504 69,398 -745 -1.06 7,524 25.23 1.6542
2015-10-16 2015-09-30 13F LIGAND PHARMACEUTICALS INC B COMMON STOCK 53220K504 70,143 -1,300 -1.82 6,008 -16.66 1.3677
2015-07-07 2015-06-30 13F LIGAND PHARMACEUTICALS INC B COMMON STOCK 53220K504 71,443 280 0.39 7,209 31.38 1.3585
2015-04-09 2015-03-31 13F LIGAND PHARMACEUTICALS INC B COMMON STOCK 53220K504 71,163 12,280 20.85 5,487 75.14 1.0181
2015-02-13 2014-12-31 13F LIGAND PHARMACEUTICALS INC B COMMON STOCK 53220K504 58,883 6,655 12.74 3,133 27.67 0.5820
2014-10-06 2014-09-30 13F LIGAND PHARMACEUTICALS INC B COMMON STOCK 53220K504 52,228 14,825 39.64 2,454 5.32 0.4721
2014-07-07 2014-06-30 13F LIGAND PHARMACEUTICALS INC B COMMON STOCK 53220K504 37,403 11,260 43.07 2,330 32.46 0.4129
2014-04-07 2014-03-31 13F LIGAND PHARMACEUTICALS INC B COMMON STOCK 53220K504 26,143 17,314 196.10 1,759 279.09 0.3272
2014-01-13 2013-12-31 13F LIGAND PHARMACEUTICALS INC B COMMON STOCK 53220K504 8,829 8,829 464 0.0843
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.